NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Sutro Biopharma, Inc. (STRO) Stock Analysis

Sutro Biopharma, Inc. (STRO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

STRO

$10.79

−$0.75 (−6.50%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare STRO with… →

STRO Key Statistics

As of Oct 21, 2026
Trading
Open
$11.62
Previous Close
$11.54
Day's Range
10.75–11.80
52-Week Range
7.15–43.85
Volume
439.85K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.50
Valuation
Market Cap
$178.91M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.91
EPS (ttm)Profit attributable to each share over the last twelve months.
−17.28
Financials (FY)
Revenue (FY)
$102.48M+65.18%
Net Income (FY)
−$191.09M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
16.58M
1-Year Return
−10.08%
Dividend and dates
Avg Volume
295.85K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, STRO closed at $10.79, −10.08% over 1 year.

Sutro Biopharma, Inc. (STRO) has a market capitalization of $178.91M.

In fiscal 2025, STRO reported revenue of $102.48M.

STRO Stock Return by Calendar Year

Sutro Biopharma, Inc. (STRO) return since Sep 2018: what $10,000 became

1 year
$10,000 $8,992
−10.08%
5 years
$10,000 $575
−94.25%
Since Sep 2018
$10,000 $710
−92.90%

If you had invested $10,000 in Sutro Biopharma, Inc. (STRO) at the close on September 27, 2018, the earliest close on record here, it would have been worth $710 at the close on October 21, 2026: −92.90% in total, −27.96% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−6.74%
2025−37.12%
2024−57.11%
2023−46.91%
2022−45.70%
2021−31.46%
2020+97.36%
2019+21.95%
2018 (partial year)−40.66%

As of October 21, 2026.

STRO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$102.48M−$191.09M−186.5%
2024$62.04M−$227.46M−366.6%
2023$153.73M−$106.79M−69.5%
2022$67.77M−$119.20M−175.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$102.48M—−$104.95M−$191.09M−186.5%
2024$62.04M—−$238.45M−$227.46M−366.6%
2023$153.73M—−$89.28M−$106.79M−69.5%
2022$67.77M—−$128.94M−$119.20M−175.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

STRO Valuation vs Biotechnology Median

Median of 608 stocks
MetricSTROBiotechnology medianvs median
P/S ratio3.9113.300.3x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Sutro Biopharma, Inc. (STRO) carries a market capitalisation of $178.91M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 128 employees.

The most recent close on file for STRO is $10.79, dated October 21, 2026. That is −$0.75 (−6.50%) against the previous close. Over the past 52 weeks the price has ranged from $7.15 to $43.85. The latest close sits 50.91% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $102.48M. Against the prior fiscal year total of $62.04M, that is a change of +65.18%. The same year closed with a net loss of $191.09M. Trailing earnings per share are −17.28.

Across the 4 fiscal years on file, revenue moves from $67.77M in 2022 to $102.48M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 3.91. On price-to-sales that is 0.3 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the total return is −10.08%. Across 5 years the annualized return works out at −43.51%. Beta against the wider market is reported at 1.5. Annualized volatility over the trailing 8 years is 85.44%.

Growth & Income

No dividend is on file for STRO.

2026 is still running; the total return is −6.74% year to date. The strongest complete calendar year on file is 2020 at +97.36%; the weakest is 2024 at −57.11%. Of the 7 complete calendar years on file, 2 finished higher.

Peer Comparison

Sutro Biopharma, Inc. (STRO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Sutro Biopharma, Inc. STRO $178.91M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Sutro Biopharma, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Sutro Biopharma, Inc.

Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, endometrial cancer, and bladder cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease in adults and adults and infants; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Visit website →